加载中
NASDAQHealthcareDrug Manufacturers - General
最新数据
US$7.235
−US$0.135 · -1.83%
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
常规交易时段
US$7.235
−US$0.135 · -1.83%
盘中时间采用ET。市场数据可能有所延迟。
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
日内区间
当前US$7.235
52周区间
当前US$7.235
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
90
深度低估
情绪
59
多空交织
风险
43
风险偏高
动量
32
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
日内区间
当前US$7.235
52周区间
当前US$7.235
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 72.27亿 EUR | 72.12亿 EUR | 65.92亿 EUR | 60.64亿 EUR | 49.33亿 EUR |
| 销货成本 | 46.47亿 EUR | 44.18亿 EUR | 41.08亿 EUR | 38.5亿 EUR | 29.71亿 EUR |
| 毛利 | 25.8亿 EUR | 27.95亿 EUR | 24.83亿 EUR | 22.14亿 EUR | 19.63亿 EUR |
| 研究与开发 | 3.58亿 EUR | 3.84亿 EUR | 3.95亿 EUR | 3.61亿 EUR | 3.55亿 EUR |
| 销售、一般及管理费用 | 10.21亿 EUR | 11.44亿 EUR | 12.66亿 EUR | 11.08亿 EUR | 10.62亿 EUR |
| 营业费用 | 13.93亿 EUR | 16.03亿 EUR | 17.01亿 EUR | 14.31亿 EUR | 13.68亿 EUR |
| 利息收入 | 3265.81万 EUR | 4805.2万 EUR | 6243万 EUR | 3385.9万 EUR | 1155.1万 EUR |
| 利息支出 | 6亿 EUR | 7.73亿 EUR | 5.16亿 EUR | 4.45亿 EUR | 2.34亿 EUR |
| 折旧和摊销 | 4.32亿 EUR | 4.38亿 EUR | 4.46亿 EUR | 4.11亿 EUR | 3.6亿 EUR |
| 营业利润 | 11.87亿 EUR | 11.92亿 EUR | 7.82亿 EUR | 7.82亿 EUR | 5.95亿 EUR |
| 净利润 | 3.86亿 EUR | 1.57亿 EUR | 4231.8万 EUR | 1.85亿 EUR | 1.89亿 EUR |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
年度分割调整后的每股现金分配。
US$0.302
2019年（完整年度）+6.0% 自从 2017
2026年（部分年度）：US$0.1058
US$0.285
2,017
US$0.3673
2,018
US$0.302
2,019
US$0.1058
2,026*
* 在现有股息历史记录中，该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月2日 | US$0.1058Annual | 2026年7月2日 | 2026年7月9日 |
股息 | 2025年8月12日 | US$0.1758Irregular | 2025年8月12日 | 2025年8月20日 |
股息 | 2021年6月3日 | US$0.3598Special | 2021年6月4日 | 2021年6月14日 |
股息 | 2020年10月30日 | US$0.1432Special | 2020年11月2日 | 2020年11月9日 |
股息 | 2019年12月2日 | US$0.1697Semi-Annual | 2019年12月3日 | 2019年12月11日 |
股息 | 2019年6月7日 | US$0.1323Special | 2019年6月10日 | 2019年6月18日 |
除息 2026年7月2日
US$0.1058
Annual
2026年7月2日登记 · 支付日 2026年7月9日
除息 2025年8月12日
US$0.1758
Irregular
2025年8月12日登记 · 支付日 2025年8月20日
除息 2021年6月3日
US$0.3598
Special
2021年6月4日登记 · 支付日 2021年6月14日
除息 2020年10月30日
US$0.1432
Special
2020年11月2日登记 · 支付日 2020年11月9日
除息 2019年12月2日
US$0.1697
Semi-Annual
2019年12月3日登记 · 支付日 2019年12月11日
除息 2019年6月7日
US$0.1323
Special
2019年6月10日登记 · 支付日 2019年6月18日
报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB1334.27万0.12%108.2亿 USD0.44%US$200.56-1.81%
Brandes International ETFBINV678.88万1.28%5.3亿 USD0.70%US$43.65+0.55%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP260.68万0.10%26.34亿 USD0.20%US$64.865-0.61%
Brandes U.S. Small-Mid Cap Value ETFBSMC253.56万1.51%1.68亿 USD0.70%US$38.43+0.32%
State Street SPDR Portfolio Developed World ex-US ETFSPDW227.85万0.01%406.96亿 USD0.03%US$49.655-0.06%
Capital Group International Core Equity ETFCGIC90.05万0.04%25.62亿 USD0.54%US$35.485-0.07%
ActivePassive International Equity ETFAPIE20.83万0.02%11.36亿 USD0.45%US$38.59+0.49%
Invesco NASDAQ Future Gen 200 ETFQQQS11.59万0.51%2275.83万 USD0.20%US$40.6683-1.80%iShares Biotechnology ETFIBBBrandes International ETFBINVState Street SPDR S&P Kensho New Economies Composite ETFKOMPBrandes U.S. Small-Mid Cap Value ETFBSMCState Street SPDR Portfolio Developed World ex-US ETFSPDWCapital Group International Core Equity ETFCGICActivePassive International Equity ETFAPIEInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
